In the present paper we tested the effects of NVP-BEZ235 in a series of five early passage primary pancreatic cancer xenografts, and show that acute oral single doses suppress signalling targets downstream from PI3K/mTor in a time-dependent manner consistent with the pharmacokinetics of the compound, and that chronic treatment produces significant growth inhibition. The gene discussed is MTOR; the disease is pancreatic neoplasm.